BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-223@pharmaconomics
DTSTAMP:20260707T003607Z
DTSTART;VALUE=DATE:20260711
DTEND;VALUE=DATE:20260712
SUMMARY:CORT PDUFA — relacorilant
DESCRIPTION:The FDA's approval decision on relacorilant for platinum-resistant ovarian cancer is due Jul 11\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/d159941dex991.htm\n\nTrack it: https://pharmaconomics.com/e/223
URL:https://pharmaconomics.com/e/223
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CORT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR